Cinctive Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cinctive Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.42M	Sell	4,508 -10,818	-71%	-$5.54M	0.09%	256
2026 Q1	$8.02M	Buy	15,326 +11,639	+316%	+$5.56M	0.52%	56
2025 Q4	$2.15M	Buy	3,687 +81	+2%	+$41.4K	0.12%	201
2025 Q3	$1.65M	Sell	3,606 -1,162	-24%	-$434K	0.08%	270
2025 Q2	$1.44M	Buy	4,768 +3,677	+337%	+$1.1M	0.08%	253
2025 Q1	$361K	Sell	1,091 -4,315	-80%	-$1.42M	0.03%	276
2024 Q4	$1.67M	Buy	5,406 +332	+7%	+$93.4K	0.08%	237
2024 Q3	$1.08M	Buy	+5,074	New	+$1.3M	0.06%	286
2024 Q1	–	Sell	-2,350	Closed	-$544K	–	467
2023 Q4	$544K	Buy	+2,350	New	+$411K	0.04%	305

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cinctive Capital Management's MDGL Position: Q2 2026 in Review

Cinctive Capital Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 71% in Q2 2026, selling an estimated $5.54M and leaving 4,508 shares worth $2.42M. The position accounts for 0.09% of the portfolio, ranked #256.

Cinctive Capital Management first reported a position in MDGL in Q4 2023 and has held it in 9 quarters since. The position peaked at $8.02M in Q1 2026. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Cinctive Capital Management held 4,508 shares of Madrigal Pharmaceuticals worth $2.42M as of Q2 2026.
Cinctive Capital Management sold 10,818 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $5.54M.
Madrigal Pharmaceuticals made up 0.09% of Cinctive Capital Management's portfolio in Q2 2026, its #256 holding.
Cinctive Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
Cinctive Capital Management's Madrigal Pharmaceuticals position peaked at $8.02M in Q1 2026.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.